The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Open accessAbstract
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for clinical treatment because of the natural or acquired drug resistance of CRPC. Mechanisms of drug resistance are extremely complicated and how to overcome it remains an urgent clinical problem to be solved. Thus, a comprehensive and thorough understanding for mechanisms of drug resistance in mCRPC is indispensable to develop novel and better therapeutic strategies. In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, androgen receptor signaling inhibitors (ARSIs) and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Most importantly, in order to improve efficacy of these drugs, strategies of overcoming drug resistance are also discussed based on their mechanisms respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Cancer—Principles & Practice of Oncology
Rhoads, J. E. (1983) · PubMed Central · Cited by 1,466
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Tumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01638 · Cited by 736
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01035 · Cited by 694
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Development and evolution of adaptive polyphenisms
Nijhout, H. F. (2003) · Evolution & Development · doi:10.1046/j.1525-142x.2003.03003.x · Cited by 652
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
Impact of the physical microenvironment on tumor progression and metastasis
Spill, F., Reynolds, D. S., Kamm, R. D., & Zaman, M. H. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.007 · Cited by 581
Annala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479
Microtubule-targeted anticancer agents and apoptosis
Bhalla, K. N. (2003) · Oncogene · doi:10.1038/sj.onc.1207233 · Cited by 461
Pettitt, S. J., Krastev, D. B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M. I., Menon, M., Brough, R., Campbell, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03917-2 · Cited by 449
Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0494 · Cited by 446
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0261 · Cited by 421
Hoskin, P., Sartor, O., O'Sullivan, J. M., Johannessen, D. C., Helle, S. I., Logue, J., Bottomley, D., Nilsson, S., Vogelzang, N. J., Fang, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70474-7 · Cited by 407
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1283 · Cited by 405
Zou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., Le Magnen, C., Chester, D., Mostaghel, E. A., Califano, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1174 · Cited by 386
Gogola, E., Duarte, A. A., de Ruiter, J. R., Wiegant, W. W., Schmid, J. A., de Bruijn, R., James, D. I., Guerrero Llobet, S., Vis, D. J., Annunziato, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.008 · Cited by 374
Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford, P. A., Dodson, A. R., PARSONS, K. F., DESMOND, A. D., Woolfenden, A., Fordham, M., Neoptolemos, J. P., Ke, Y., & Foster, C. S. (2000) · PubMed · Cited by 365
Liu, C., Lou, W., Zhu, Y., Nadiminty, N., Schwartz, C. T., Evans, C. P., & Gao, A. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3296 · Cited by 348
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 336
Drug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
Long non-coding RNAs and human disease
Harries, L. W. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120020 · Cited by 336
Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Parnis, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00580-8 · Cited by 335
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08008 · Cited by 293
Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02031 · Cited by 285
Schrader, A. J., Boegemann, M., Ohlmann, C.-H., Schnoeller, T. J., Krabbe, L.-M., Hajili, T., Jentzmik, F., Stoeckle, M., Schrader, M., Herrmann, E., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.042 · Cited by 284
Mierke, C. T. (2019) · Reports on Progress in Physics · doi:10.1088/1361-6633/ab1628 · Cited by 262
Rathkopf, D. E., Morris, M. J., Fox, J. J., Danila, D. C., Slovin, S. F., Hager, J. H., Rix, P. J., Chow Maneval, E., Chen, I., Gönen, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.1684 · Cited by 261
Fallah, J., Agrawal, S., Gittleman, H., Fiero, M. H., Subramaniam, S., John, C., Chen, W., Ricks, T. K., Niu, G., Fotenos, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2875 · Cited by 255
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
Galletti, G., Leach, B. I., Lam, L., & Tagawa, S. T. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.008 · Cited by 216
ter Brugge, P., Kristel, P., van der Burg, E., Boon, U., de Maaker, M., Lips, E., Mulder, L., de Ruiter, J., Moutinho, C., Gevensleben, H., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw148 · Cited by 211
Lipovich, L., Johnson, R., & Lin, C.-Y. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.10.001 · Cited by 201
Collins, A. T., & Maitland, N. J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.037 · Cited by 198
Fizazi, K., Massard, C., Bono, P., Jones, R., Kataja, V., James, N., Garcia, J. A., Protheroe, A., Tammela, T. L., Elliott, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70240-2 · Cited by 196
Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
Yu, Z., Chen, S., Sowalsky, A. G., Voznesensky, O. S., Mostaghel, E. A., Nelson, P. S., Cai, C., & Balk, S. P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1863 · Cited by 196
Galsky, M. D., Dritselis, A., Kirkpatrick, P., & Oh, W. K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3254 · Cited by 173
Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., McEachern, D., Wang, Y., Metwally, H., Wang, L., Matvekas, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00882 · Cited by 170
Kwak, E. L., Ahronian, L. G., Siravegna, G., Mussolin, B., Borger, D. R., Godfrey, J. T., Jessop, N. A., Clark, J. W., Blaszkowsky, L. S., Ryan, D. P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0748 · Cited by 169
Ploussard, G., Terry, S., Maillé, P., Allory, Y., Sirab, N., Kheuang, L., Soyeux, P., Nicolaiew, N., Coppolani, E., Paule, B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1447 · Cited by 161
Yadav, M. P., Ballal, S., Sahoo, R. K., Tripathi, M., Seth, A., & Bal, C. (2020) · Theranostics · doi:10.7150/thno.48107 · Cited by 158
Fizazi, K. S., Jones, R. J., Oudard, S. M., Efstathiou, E., Fred Saad, C., de Wit, R., Bono, J. S. D., Cruz, F. M., Fountzilas, G., Ulys, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5119 · Cited by 156
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Drost, R., Dhillon, K. K., van der Gulden, H. M. L., van der Heijden, I., Brandsma, I., Cruz, C., Chondronasiou, D., Castroviejo‐Bermejo, M., Boon, U., Schut, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci70196 · Cited by 146
Tagawa, S. T., Vallabhajosula, S., Christos, P. J., Jhanwar, Y. S., Batra, J. S., Lam, L., Osborne, J. R., Beltran, H., Molina, A. M., Goldsmith, S. J., et al. (2019) · Cancer · doi:10.1002/cncr.32072 · Cited by 145
Chen, Q., van der Sluis, P. C., Boulware, D. C., Hazlehurst, L., & Dalton, W. S. (2005) · Blood · doi:10.1182/blood-2004-11-4286 · Cited by 143
Fred Saad, C., Fizazi, K. S., Jinga, V., Efstathiou, E., Fong, P. C. C., Hart, L. L., Jones, R. J., McDermott, R., Wirth, M. P., Suzuki, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70027-6 · Cited by 126
Hussain, M., Corcoran, C., Sibilla, C., Fizazi, K. S., Fred Saad, C., Shore, N., Sandhu, S., Mateo, J., Olmos, D., Mehra, N., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3940 · Cited by 117
Advancing a clinically relevant perspective of the clonal nature of cancer
Ruiz, C. F., Lenkiewicz, E., Evers, L., Holley, T., Robeson, A., Kiefer, J., Demeure, M. J., Hollingsworth, M. A., Shen, M., Prunkard, D. E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104009108 · Cited by 111
Kallio, H. M. L., Hieta, R., Latonen, L., Brofeldt, A., Annala, M., Kivinummi, K. K., Tammela, T. L. J., Nykter, M., Isaacs, W. B., Lilja, H. G., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0172-0 · Cited by 108
Nanoways to overcome docetaxel resistance in prostate cancer
Ganju, A., Yallapu, M. M., Khan, S., Behrman, S. W., Chauhan, S. C., & Jaggi, M. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.04.001 · Cited by 101
Xie, T., Fu, D.-J., Li, Z., Lv, D., Song, X., Yu, Y., Wang, C., Li, K., Zhai, B., Wu, J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01630-9 · Cited by 97
Self-citationAndrogen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
Ehsani, M., David, F. O., & Baniahmad, A. (2021) · Cancers · doi:10.3390/cancers13071534 · Cited by 93
Increased expression of class III β-tubulin in castration-resistant human prostate cancer
Terry, S., Ploussard, G., Allory, Y., Nicolaïew, N., Boissière‐Michot, F., Maillé, P., Kheuang, L., Coppolani, E., Ali, A., Bibeau, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605245 · Cited by 90
CYP17A1 inhibitors in castration-resistant prostate cancer
Gomez, L., Kovac, J. R., & Lamb, D. J. (2015) · Steroids · doi:10.1016/j.steroids.2014.12.021 · Cited by 90
Rathkopf, D. E., Antonarakis, E. S., Shore, N. D., Tutrone, R. F., Jr., Alumkal, J. J., Ryan, C. J., Saleh, M. N., Hauke, R. J., Bandekar, R. R., Maneval, E. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2509 · Cited by 89
James, N. D., Pirrie, S. J., Pope, A., Barton, D., Andronis, L., Goranitis, I., Collins, S. I., Daunton, A., McLaren, D. B., O’Sullivan, J. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5570 · Cited by 88
Cross-resistance and drug sequence in prostate cancer
Buck, S. A. J., Koolen, S. L. W., Mathijssen, R. H. J., de Wit, R., & van Soest, R. J. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100761 · Cited by 88
Targeting the glucocorticoid receptor in breast and prostate cancers
Kach, J., Conzen, S. D., & Szmulewitz, R. Z. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7531 · Cited by 74
Overview of the latest treatments for castration-resistant prostate cancer
Bishr, M., & Fred Saad, C. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.137 · Cited by 73
Yu, E. Y., Piulats, J. M., Gravis, G., Fong, P. C. C., Todenhöfer, T., Laguerre, B., Arranz, J. Á., Oudard, S. M., Massard, C., Heinzelbecker, J., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.08.005 · Cited by 73
Self-citationBone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
Mollica, V., Rizzo, A., Rosellini, M., Marchetti, A., Ricci, A. D., Cimadamore, A., Scarpelli, M., Bonucci, C., Andrini, E., Errani, C., et al. (2021) · Cancers · doi:10.3390/cancers13030546 · Cited by 68
Ruiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65
Alterations in γ-Actin and Tubulin-Targeted Drug Resistance in Childhood Leukemia
Verrills, N. M., Po’uha, S. T., Liu, M. L. M., Liaw, T. Y. E., Larsen, M. R., Ivery, M. T. G., Marshall, G. M., Gunning, P. W., & Kavallaris, M. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj372 · Cited by 63
Crnalic, S., Hörnberg, E., Wikström, P., Lerner, U. H., Tieva, Å., Svensson, O., Widmark, A., & Bergh, A. R. J. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0059 · Cited by 61
High Progesterone Receptor Expression in Prostate Cancer Is Associated with Clinical Failure
Grindstad, T., Andersen, S., Al‐Saad, S., Dønnem, T., Kiselev, Y., Melbø‐Jørgensen, C., Skjefstad, K., Busund, L., Bremnes, R. M., & Richardsen, E. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116691 · Cited by 52
Hirayama, Y., Tam, T. W., Jian, K., Andersen, R. J., & Sadar, M. D. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12770 · Cited by 52
The pharmacological point of view of resistance to therapy in tumors
Damia, G. L. M., & Garattini, S. K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.008 · Cited by 49
Liu, H., Han, R., Li, J., Liu, H., & Zheng, L. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9992-2 · Cited by 46
Giraudet, A., Kryza, D., Hofman, M. S., Moreau, A., Fizazi, K. S., Fléchon, A., Hicks, R. J., & Tran, B. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211053898 · Cited by 44
Smith, M. R., Fred Saad, C., Rathkopf, D. E., Mulders, P., Bono, J. S. D., Small, E. J., Shore, N. D., Fizazi, K. S., Kheoh, T. S., Li, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.007 · Cited by 43
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
Narayanan, R. (2020) · Asian journal of urology · doi:10.1016/j.ajur.2020.03.002 · Cited by 43
Interference with the androgen receptor protein stability in therapy‐resistant prostate cancer
Lakshmana, G., & Baniahmad, A. (2018) · International Journal of Cancer · doi:10.1002/ijc.31818 · Cited by 40
ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 38
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
Yehya, A., Ghamlouche, F., Zahwe, A., Zeid, Y., Wakimian, K., Mukherji, D., & Abou-Kheir, W. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.15 · Cited by 37
Fred Saad, C., Thiery-Vuillemin, A., Wiechno, P., Alekseev, B. Y., Sala, N., Jones, R., Kocák, I., Chiurì, V. E., Jassem, J., Fléchon, A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00498-3 · Cited by 33
“Drug resistance associated membrane proteins”
Sherlach, K. S., & Roepe, P. D. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00108 · Cited by 23
Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
Chen, M., Liang, Z.-J., Luo, D., Xue, K., Liao, D.-Y., Li, Z., Yu, Y., Chen, Z., & Zhao, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.843110 · Cited by 16
Self-citation
Cited by
Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D’Agostino, E., Pirola, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094624 · Cited by 15
Metadata
- Authors
- Cai, M., Song, X.-L., Li, X.-A., Chen, M., Guo, J., Yang, D.-H., Chen, Z., & Zhao, S.-C.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 68
- Pages
- 100962
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W4365517625
- Cited by
- 262
- References
- 117
- FWCI
- 42.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.